SOPHHealthcare · Health Information ServicesThe 5 Wall Street analysts covering SOPHiA GENETICS SA hold a median 12-month price target of $8.5 — +27.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 6 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores SOPHiA GENETICS SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Value (18): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own SOPHiA GENETICS SA — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on SOPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +27.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | HC Wainwright & Co. | Initiates | Buy | $12 |
| 15 June 2026 | BTIG | Reiterates | Buy | — |
| 15 June 2026 | BTIG | Reiterates | Buy | $8.00 |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 15 Apr 2026 | BTIG | Maintains | Buy | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 10 Nov 2025 | BTIG | Maintains | Buy | — |
| 18 Dec 2024 | Craig-Hallum | Initiates | Buy | — |
| 7 Aug 2024 | RBC Capital | Maintains | Outperform | — |
| 27 June 2024 | Guggenheim | Initiates | Buy | — |
| 6 Mar 2024 | BTIG | Maintains | Buy | — |
| 6 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Jan 2024 | RBC Capital | Reiterates | Outperform | — |
| 29 Nov 2023 | RBC Capital | Initiates | Outperform | — |
| 10 May 2023 | Credit Suisse | Maintains | Neutral | — |
| 10 May 2023 | Morgan Stanley | Maintains | Overweight | — |
| 8 Mar 2023 | Morgan Stanley | Maintains | Overweight | — |
| 3 Jan 2023 | BTIG | Initiates | Buy | — |
| 23 Nov 2022 | Credit Suisse | Initiates | Neutral | — |
| 9 Nov 2022 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 21% of US stocks
Cheaper than 11% of US stocks
Cheaper than 81% of US stocks
Higher than 78% of US stocks
Higher than 63% of US stocks
Higher than 81% of US stocks
Higher than 15% of US stocks
Higher than 6% of US stocks
Higher than 13% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOPH appears on the weeks it earns a place.
SOPHiA GENETICS SA published the transcript of its Q2 2026 earnings call via Seeking Alpha. The excerpt confirms the call and transcript took place but provides no details on results or commentary.
Why it matters — SOPH watchers would turn to this transcript for direct management discussion of the company's Q2 2026 financial performance and outlook.
SOPHiA GENETICS reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, citing accelerating U.S. adoption, liquid biopsy momentum, and new biopharma agreements.
Why it matters — The raised outlook and faster growth indicate strengthening demand for SOPHiA's precision medicine software across U.S. and biopharma markets.
SOPHiA GENETICS reported Q2 2026 results, with revenue of $23.3 million (up 27% year-over-year), a reported gross margin of 64.6%, a net loss of $22.4 million flat year-over-year, and an adjusted EBITDA loss of $8.8 million improving 27% year-over-year. The company raised its 2026 revenue guidance to $94–96 million, representing 22–24% year-over-year growth.
Why it matters — The report shows accelerating revenue growth, a narrower adjusted EBITDA loss, and an upward revision to full-year guidance, offering a direct update on SOPH's financial trajectory.
SOPHiA GENETICS announced a new multi-year global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The agreement advances the development and commercialization of two CDx programs, applying SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.
Why it matters — A SOPH watcher would care because the collaboration expands SOPHiA GENETICS's companion diagnostic pipeline and commercial reach through a multi-year partnership with a major pharmaceutical company.
The 5 Wall Street analysts covering SOPHiA GENETICS SA have a median 12-month price target of $8.5, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering SOPHiA GENETICS SA, 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SOPHiA GENETICS SA 53 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Aug 2026, SOPHiA GENETICS SA ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +27.1% from the last close, and Ticker Nerd's factor model ranks SOPHiA GENETICS SA 53 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SOPHiA GENETICS SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.
SOPHiA GENETICS SA returned +112.5% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
SOPHiA GENETICS SA is a healthcare technology company specializing in AI-powered, cloud-native software for data-driven medicine. Headquartered in Rolle, Switzerland and founded in 2011, the company focuses on enabling hospitals, laboratories, and biopharma institutions to analyze complex health data, particularly in oncology and rare genetic disorders.
The most recent item we track (Seeking Alpha, 4 Aug 2026): "SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript". SOPHiA GENETICS SA published the transcript of its Q2 2026 earnings call via Seeking Alpha. The excerpt confirms the call and transcript took place but provides no details on results or commentary.
SOPHiA GENETICS SA is a healthcare technology company specializing in AI-powered, cloud-native software for data-driven medicine. Headquartered in Rolle, Switzerland and founded in 2011, the company focuses on enabling hospitals, laboratories, and biopharma institutions to analyze complex health data, particularly in oncology and rare genetic disorders. Its core offering is the SOPHiA DDM Platform, a consumption-based Software-as-a-Service solution that standardizes and interprets multimodal data, including genomic, radiomic, clinical, biological, and digital pathology information, to generate actionable insights for patient care and research. SOPHiA GENETICS supports a broad global customer network, providing applications across cancer, inherited and rare diseases, infectious diseases, cardiology, neurology, and other specialties. The company’s technology is used both in clinical workflows and by biopharma partners for drug discovery and development, positioning SOPHiA GENETICS as a key provider of medical software and technology services in precision medicine and advanced diagnostics.
CEO Mr. Ross Jordan Muken B.Sc. · 415 employees · Switzerland · https://www.sophiagenetics.com